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Background: Endostatin is an endogenous inhibitor of angiogenesis that inhibits neovascularisation. The aim of the
study was to evaluate the effect of elective surgery on endostatin levels.
Methods: Blood samples were collected prior to elective surgery and 4 and 30 days postoperatively in 2 patient
groups: orthopedic surgery (n =27) and coronary bypass patients (n =21). Serum endostatin levels were measured
by ELISA.
Results: Serum endostatin was significantly reduced 30 days after surgery in comparison with presurgical values in
both the orthopedic (P =0.03) and cardiopulmonary surgery (P =0.04) group.
Conclusion: Serum endostatin is reduced 30 days after surgery. This reduction would favor angiogenesis and
wound-healing.
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Collagen XVIII is a basement membrane protein with
structural similarities to collagen XV [1,2]. Collagen XVIII
contains an anti-angiogenic C-terminal non-collagenous
domain known as endostatin [3,4]. Endostatin has a mo-
lecular weight of 22 kDa and is an endogenous inhibitor
of angiogenesis formed by the proteolytic cleavage of the
C-terminal domain [5]. The formation of endostatin is
mainly induced by elastase, metalloproteinases (MMP) -3,
-7, -9, -13, -14 and -20, and cathepsin L [6-8].
Endostatin plays a role in the local balance of angio-
genesis as a potent inhibitor and has been suggested to
be of particular importance in the growth and spreading
of malignant diseases. Endostatin has been shown to in-
hibit the growth of several tumors of both human and
mouse origin [9-13]. Angiogenesis is also important for
physiological wound-healing. Healing of cutaneous
wounds in mice may be inhibited by recombinant endo-
statin treatment [14]. Overexpression of endostatin in* Correspondence: torbjorn.akerfeldt@akademiska.se
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unless otherwise stated.keratinocytes has also been shown to delay wound-
healing [15]. Endostatin has also been shown to inhibit
wound repair of lung epithelial cells [16], and to impair
healing of gastric ulcers [17].
The endostatin levels in surgical patients may thus
influence the rate of wound-healing. Delayed wound-
healing is an important surgical problem and it is associ-
ated with increased complications such as infections and
also increased mortality [18-21].
The aim of the present study was to investigate the
effect of postsurgical inflammation on serum endostatin
levels in humans. The patients were treated with elective
surgery, and thus the patients had low presurgical inflam-
matory activities. The operations induce a strong inflam-
matory response and thus are suitable for investigating
the effects of traumatic inflammatory response on serum
endostatin levels during the wound-healing period [22].
Results from two surgery groups were compared to
strengthen the significance of any findings.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Endostatin and C-reactive protein (CRP) values in










































































Figure 2 Endostatin and C-reactive protein (CRP) values in
individual patients at day 0, day 4 and day 30 after
cardiopulmonary bypass surgery.
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Study population
Elective orthopedic surgery (n =27, 13 males and 14
females) and elective cardiopulmonary bypass surgery
(n =21, 18 males and 3 females) patients, at the Uppsala
University Hospital were included in the study. Blood
sampling was performed prior to surgery and on day 4
and day 30 after surgery. The blood samples were col-
lected in Vacutainer tubes (367815, Becton, Dickinson,
Franklin Lakes, NJ, USA) without additives, and after clot-
ting the samples were centrifugated at room temperature
and the sera were collected and frozen at −22°C. The
study was approved by the local ethical board at Uppsala
University (2004:237) and all patients signed an informed
consent prior to inclusion in the study.
C-reactive protein (CRP) assay
Serum CRP (reagent: 6 K2601) was analyzed on an
Architect Ci8200 analyzer (Abbott Laboratories, Abbott
Park, IL, USA). The CRP assay had a total coefficient of
variation (CV) of 0.8% at 8 mg/L and the assay calibra-
tor was traceable to CRM 470.
Endostatin ELISA
Serum levels of endostatin were analyzed using a com-
mercially available ELISA kit for endostatin (DY1098,
R&D Systems, Minneapolis, MN, USA). The assays had
a total coefficient of variation (CV) of approximately 6%.
Statistical calculations
Statistical analysis was performed with Statistica 7.1
(StatSoft, Tulsa, OK, USA). Comparisons between pre-
surgical and postsurgical samples were performed with
the Wilcoxon matched pair test. Association between
endostatin and CRP was investigated with Spearman
rank correlation. Descriptive statistics for the different
sampling times were reported as median and IQR (inter-
quartile range). P <0.05 was regarded as statistically sig-
nificant throughout the study.
Results
Patient characteristics and CRP values
The mean age was 67 years (range 45 to 80 years) for
the orthopedic patients and 69 years (range 48 to
84 years) for the cardiopulmonary bypass patients. In
the orthopedic group (Figure 1), median CRP value prior
to surgery was 1.9 mg/L (IQR 1.2 – 8.7). Four days after
surgery the median value was 137.3 mg/L (IQR 104.1 –
178.2) and 30 days after surgery the median value was
5.1 mg/L (IQR 2.1 – 11.2). The corresponding values for
the cardiopulmonary surgery group (Figure 2) was: CRP
value prior to surgery 3.3 mg/L (IQR 1.0 – 7.6), 4 days
after surgery 167.0 mg/L (103.7 – 222.7) and 30 days
after surgery 3.4 mg/L (2.0 – 5.6).Endostatin values
In the orthopedic group (Figure 1) the presurgical median
endostatin value was 98.1 ng/mL (IQR 79.3 – 114.2). Four
days after surgery the median value was 92.8 ng/mL (IQR
76.7 – 106.9) (P =0.23) and 30 days after surgery the me-
dian value was 86.2 ng/mL (IQR 77.7 – 95.3) (P =0.03
versus presurgical values). The median endostatin value
in the cardiopulmonary surgery group (Figure 2) was
90.0 ng/mL (IQR 81.9 – 105.5). Four days after surgery
the median values was 88.1 ng/mL (IQR 77.5 – 112.1)
(P =0.85) and 30 days after surgery the median value
was 76.9 ng/mL (IQR 67.3 – 90.8) (P =0.04 versus pre-
surgical values).
Table 1 Spearman rank correlations between C-reactive
protein (CRP) and endostatin at day 0, day 4 and day 30 in
the orthopedic and the cardiopulmonary surgery groups
Orthopedic surgery R P-value
Day 0 0.35 0.071
Day 4 0.44 0.020
Day 30 0.31 0.15
Cardiopulmonary surgery
Day 0 0.43 0.055
Day 4 0.54 0.012
Day 30 0.29 0.31
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There were significant Spearman rank correlations be-
tween endostatin and CRP at day 4 in both the orthopedic
(R =0.44, P =0.020) and the cardiopulmonary surgery
(R =0.54, P =0.012) groups (Table 1). The Spearman
rank correlations between endostatin and CRP at day 0
and day 30 did not fulfill the preset criteria for signifi-
cance in this study (P <0.05).
Discussion
Apart from being a breakdown product from collagen
XVIII, endostatin is a potent endogenous angiogenesis
inhibitor and is regulated in balance with vascular endo-
thelial growth factor (VEGF) [10]. Endostatin has been
shown to be a marker of breakdown and remodelling of
the extracellular matrix in various diseases [23-25].
Therefore, one plausible explanation for the present as-
sociations could be that circulating endostatin also mir-
rors an increased extracellular remodelling. The surgical
procedures result in local tissue damage leading to the
initiation of an acute phase reaction and a wound-
healing process involving cutaneous, subcutaneous and
deeper tissues. The highest CRP values were observed
4 days after surgery. At this sampling time there was a
positive Spearman rank correlation between CRP and
endostatin concentrations in both patient groups. Thus,
during the acute phase there was a positive correlation
between inflammatory response and endostatin values.
At the same time there was a postoperative endostatin
decrease during the postsurgical phase. This indicated
that there were several pathways that influenced endo-
statin concentrations after surgery. One of the influential
factors appeared to be the inflammatory response al-
though the surgical process initiated other systems that
led to a decrease in endostatin levels.
Conclusions
The largest difference in serum concentration of endo-
statin was generated between the samples ‘before surgery’
and ‘day 30’. At day 4 the wound-healing process had just
been initiated while it was more active at day 30. Thedecline in endostatin concentrations favors neovascu-
larisation, which is of importance for wound-healing.
Further studies are warranted to explore the different
mechanisms that influence endostatin during the wound-
healing process.
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